Company news

Dimerix Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

1st ACTION3 site in Japan activated and milestone triggered

May 29, 2025

Successful planned IDMC review of ACTION3 trial

May 21, 2025

Dimerix receives initial upfront payment from Amicus

May 5, 2025

Investor Webinar and Presentation

April 30, 2025

Dimerix Licenses DMX-200 in the US

April 30, 2025

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

April 30, 2025

Trading Halt

April 28, 2025

FDA confirms Proteinuria as Primary Endpoint for US approval

April 27, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Dimerix receives initial upfront payment from FUSO

March 3, 2025

Half-Year Financial Report & Appendix 4D - 31 December 2024

February 24, 2025

First Paediatric Patient Recruited for ACTION3

January 15, 2025

Dimerix enters Development and License Agreement for Japan

January 6, 2025

DMX-200 ACTION3 Phase 3 Trial Part 2 Recruitment Complete

December 29, 2024

Dimerix Receives $7.9M R&D Tax Incentive Rebate

November 14, 2024

NEPTUNE Study Network to Enhance Phase 3 Recruitment in US

October 31, 2024

Project PARASOL Update & Medical Advisory Board Appointment

October 27, 2024

ACTION3 Trial Recruitment and Multiregion Trial Site Update

September 15, 2024

First Paediatric Site Activated and Trial Update

September 11, 2024

First patient enters into Open Label Extension study

September 10, 2024

Preliminary Final Report

August 28, 2024

Adolescent Recruitment into ACTION3 Clinical Trial

July 3, 2024

Dimerix and Taiba enter into License Agreement for DMX-200

May 26, 2024

Dimerix Receives PIP Approval from the UK MHRA

April 30, 2024

Dimerix Completes $20M Placement

March 11, 2024

Dimerix Successfully Passes Efficacy Interim Analysis

March 10, 2024

PH3 Data Collection Complete for First Interim Analysis

February 26, 2024

Half-Year Financial Report & Appendix 4D - 31 December 2023

February 25, 2024

ACTION3 IND Approved in China

November 27, 2023

Dimerix Receives Initial Upfront Payment from Advanz Pharma

November 5, 2023

Dimerix Announces License Agreement for EU, Canada, ANZ

October 4, 2023

FDA Approves Qytovra Brand Name

September 24, 2023

Regulatory Approval received in Malaysia for ACTION3 Study

September 21, 2023

Dimerix Receives $8.9M R&D Tax Incentive Rebate

September 12, 2023

Successful Completion of 2nd DSMB Review of FSGS Trial

August 7, 2023

DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24

July 23, 2023

Approval received for Paediatric Investigation Plan from EMA

July 4, 2023

Dimerix confirms Phase 3 study design appropriate for China

July 2, 2023

Prospectus

June 26, 2023

Dimerix Announces Update on Successful Capital Raise

June 5, 2023

Rights Issue Prospectus

May 4, 2023

Reinstatement to Official Quotation

May 3, 2023

Entitlement offer and Convertible Note to raise $12 million

May 3, 2023

Voluntary Suspension

May 2, 2023

Half-Year Financial Report & Appendix 4D - 31 December 2022

February 26, 2023

DXB to Receive $2.8m in Prepayment of R&D Tax Incentive

February 16, 2023

Successful Completion of DSMB Review of Phase 3 FSGS Trial

February 8, 2023

FDA Confirms Inclusion of Paediatrics in ACTION3 Study

January 11, 2023

DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved

December 14, 2022

CLARITY 2.0 COVID-19 Study Outcome

December 12, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 86 decks. Every deck is listed under its year.